Zydus secures rights to market MonoFerric in India and Nepal

13 Sep 2022 , 01:33 AM

Zydus Lifesciences has acquired rights to market MonoFerric iron isomaltoside injections in India and Nepal from Denmark based Pharmacosmos AS MonoFerric iron isomaltoside 1000 solution for injectioninfusion is a rapid single dose IV iron up to 20 mgkg bodyweight developed to reduce the number of infusions required to achieve iron correction with an excellent safety profile MonoFerricis indicated for the treatment of iron deficiency in adult patients when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly MonoFerric is available in over 30 countries including US and Europe and over 28 million doses have been administered since launch